Evidence supporting the use of: Puerarin
For the health condition: Osteoporosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Puerarin, an isoflavone derived from the root of Pueraria lobata (Kudzu), has been studied for its potential effects in supporting or treating osteoporosis, particularly in postmenopausal models. The scientific rationale centers on its phytoestrogenic activity, as it can bind to estrogen receptors and modulate bone metabolism, which is crucial since estrogen deficiency is a major factor in postmenopausal osteoporosis. Several in vitro and animal studies have reported that puerarin can stimulate osteoblast activity (bone formation) and inhibit osteoclast differentiation (bone resorption), leading to improved bone mineral density and microarchitecture in ovariectomized rat models. These effects have been linked to modulation of signaling pathways such as Wnt/β-catenin and inhibition of RANKL-mediated osteoclastogenesis.

However, clinical evidence in humans is limited. Most of the current data are preclinical, and while promising, do not yet provide strong support for widespread clinical use. There are very few, if any, well-designed randomized controlled trials in humans assessing puerarin's efficacy or safety for osteoporosis. As such, the evidence supporting its use is preliminary, giving it a rating of 2 out of 5. Ongoing and future clinical studies are needed to confirm whether these benefits translate to human populations.

More about Puerarin
More about Osteoporosis

Products containing Puerarin

We currently have no products on Vitabase that contain this ingredient.